

Keytruda® (pembrolizumab) - New indication

- On December 19, 2018, <u>Merck announced</u> the FDA approval of <u>Keytruda (pembrolizumab)</u> for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
 - This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
- Keytruda is also indicated for the treatment of melanoma, as a single agent for non-small cell lung cancer (NSCLC) with PD-L1 expression, in combination with other agents for nonsquamous or squamous NSCLC, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient solid tumors or colorectal cancer, gastric cancer, cervical cancer, and hepatocellular carcinoma.
- According to the <u>American Cancer Society</u>, MCC is a rare and dangerous type of skin cancer that is likely to spread to other parts of the body. About 2,000 cases of MCC are diagnosed in the U.S. each year.
- The new indication of Keytruda was based on the KEYNOTE-017 study enrolling 50 adult patients
 with recurrent locally advanced or metastatic MCC who had not received prior systemic therapy for
 their advanced disease. Patients received Keytruda 2 mg/kg every 3 weeks until unacceptable
 toxicity, disease progression, or up to 24 months if no disease progression. The major efficacy
 outcome measures were objective response rate (ORR) and duration of response.
 - The ORR was 56% (95% CI: 41, 70).
 - The duration of response was 5.9 to 34.5+ months.
 - Efficacy for pediatric patients with MCC is extrapolated from the results in the adult population.
- The most common adverse reactions (≥ 20%) with single-agent Keytruda use were fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.
- The recommended dosage of Keytruda in adult and pediatric patients with MCC is 200 mg and 2 mg/kg (up to a maximum of 200 mg), respectively, administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
 - Refer to the Keytruda drug label for dosing for all other indications.



optumrx.com

Optum Rx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

 $All \ Optum^{@} trademarks \ and \ logos \ are \ owned \ by \ Optum, \ Inc. \ All \ other \ brand \ or \ product \ names \ are \ trademarks \ or \ registered \ marks \ of \ their \ respective \ owners.$

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.